2014年戦略提言:イギリスの臨床化学・免疫診断市場

◆英語タイトル:2014 Strategies for the UK Clinical Chemistry and Immunodiagnostics Market
◆商品コード:VPCC4321-2-3-4
◆発行会社(リサーチ会社):Venture Planning Group
◆発行日:2014年1月
◆ページ数:※レポート概要をご参照ください。
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:※レポート概要をご参照ください。
◆販売価格オプション(消費税別)
Local LicenseUSD6,100 ⇒換算¥689,300見積依頼/購入/質問フォーム
Global LicenseUSD13,400 ⇒換算¥1,514,200見積依頼/購入/質問フォーム
DataPackUSD3,950 ⇒換算¥446,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVenture Planning Group社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Venture Planning Group社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Complete report $6,100.  DataPack (test volumes, sales forecasts, supplier shares) $3,950.

2014 Strategies for the UK Clinical Chemistry and Immunodiagnostic Market” is a new strategic analysis of major business opportunities emerging in the UK clinical chemistry and immunodiagnostic markets during the next five years.  The report explores future trends in the UK market; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.

The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.

Rationale

The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.  Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology.  This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.

Strategic Recommendations

- New product development opportunities
with significant market appeal.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Competitive Assessments

- Strategic assessments of major suppliers and
emerging market entrants, including their sales, product
portfolios, marketing tactics, collaborative
arrangements and new products in R&D. 

- The companies analyzed in the report include
Abbott, AdnaGen, Agilent, Alere, Beckman Coulter/Danaher,
Biomedical Diagnostics, bioMerieux, Bio-Rad, DiaSorin,
Eiken, Fujirebio/Innogenetics, IL, Kyowa Medex,
Ortho-Clinical Diagnotics, Roche, Siemens, Sysmex,
Thermo Fisher, Tosoh, Wako, Wallac/PE.

Tests Analyzed in the Report:

Routine Clinical Chemistry

Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total,
BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride,
Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose,
HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus,
Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid.

Therapeutic Drug Monitoring (TDM)

Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam,
Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus,
Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.

Endocrine Function

Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,
Prolactin, T3, T3 Uptake,  Free T3, T4, Free T4, TBG, Testosterone,
Thyroglobulin Ab,  TPO Ab, TSH.

Tumor Markers and Special Chemistry

AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid),
Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,
PAP, PSA, Thyroglobulin, Vitamin B-12.

Immunoproteins

C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,
Immunofixation, Prealbumin, Protein Electrophoresis.

Drugs of Abuse

Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,
LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP),
Propoxyphene, Tricyclic Antidepressants.

Market Segmentation Analysis

- Comprehensive review of the market
dynamics, trends, structure, size, growth,
and key suppliers.

- Test volume and sales forecasts for over 100 clinical chemistry,
TDM, endocrine, cancer, immunoprotein and abused drug assays,
by market segment:
    
     ° Hospitals
     ° Commercial/Private Laboratories

Current and Emerging Products

- Analysis of current and emerging clinical chemistry
and immunodiagnostic tests.

- Review of current instrumentation technologies, and feature comparison
of high-, medium-, and low-volume/POC analyzers.

Technology Review

- Assessment of current and emerging
technologies, and their potential  market applications.

- Comprehensive lists of companies developing
or marketing new technologies and products by test.

Contains 563 pages and 103 tables
 

【レポートの目次】

※目次は下記のURLでご確認ください。

http://www.vpgcorp.com/webfiles/CC/TOCLOT%20UKCCandImmunodiagnosticMarketSalesForecastsSupplierSharesCompetitiveStrategies.pdf



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[2014年戦略提言:イギリスの臨床化学・免疫診断市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆